Institutional investors in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) lost 25% last week but have reaped the benefits of longer-term growth

In This Article:

Key Insights

  • Significantly high institutional ownership implies Y-mAbs Therapeutics' stock price is sensitive to their trading actions

  • A total of 8 investors have a majority stake in the company with 53% ownership

  • Insiders have sold recently

If you want to know who really controls Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB), then you'll have to look at the makeup of its share registry. We can see that institutions own the lion's share in the company with 49% ownership. Put another way, the group faces the maximum upside potential (or downside risk).

Institutional investors endured the highest losses after the company's market cap fell by US$167m last week. However, the 112% one-year return to shareholders may have helped lessen their pain. But they would probably be wary of future losses.

In the chart below, we zoom in on the different ownership groups of Y-mAbs Therapeutics.

View our latest analysis for Y-mAbs Therapeutics

ownership-breakdown
NasdaqGS:YMAB Ownership Breakdown November 18th 2024

What Does The Institutional Ownership Tell Us About Y-mAbs Therapeutics?

Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.

As you can see, institutional investors have a fair amount of stake in Y-mAbs Therapeutics. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at Y-mAbs Therapeutics' earnings history below. Of course, the future is what really matters.

earnings-and-revenue-growth
NasdaqGS:YMAB Earnings and Revenue Growth November 18th 2024

Our data indicates that hedge funds own 9.1% of Y-mAbs Therapeutics. That's interesting, because hedge funds can be quite active and activist. Many look for medium term catalysts that will drive the share price higher. Wg Biotech Aps is currently the largest shareholder, with 10% of shares outstanding. In comparison, the second and third largest shareholders hold about 9.1% and 7.4% of the stock.

We did some more digging and found that 8 of the top shareholders account for roughly 53% of the register, implying that along with larger shareholders, there are a few smaller shareholders, thereby balancing out each others interests somewhat.

While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. Quite a few analysts cover the stock, so you could look into forecast growth quite easily.

Waiting for permission
Allow microphone access to enable voice search

Try again.